摘要
过去的几年里,绝经后骨质疏松领域有了一些重要的研究发现。长期持续的双膦酸盐类药物治疗会提高患者非典型股骨骨折的风险。在骨折高风险的绝经后患者中,特立帕肽和狄诺塞麦联合治疗组与两药分别单用组相比,联合治疗组患者的骨密度明显增加。目前,一些治疗骨质疏松新的策略正处于不同的研究阶段,如组织蛋白酶K抑制剂、重组甲状旁腺激素。
During the past 1 to 2 years,there＇re some important discoveries in the domain of postmenopausal osteoporosis. Study showed the risk for vertebral fractures became obviously higher for women who were continuously taking Azole phosphonic acid drugs. In postmenopausal patients with high risk of fracture, by comparing with the eombined medication group using Teriparatide and Prolia with the separate medication group, it was found out that bone mineral density in patients with combined medication was obviously increased. Some new treatment strategy for osteoporosis is now in different stages of development, e. g. , cathepsin K inhibitor and recombinant parathyroid hormone.
出处
《中国药业》
CAS
2015年第18期135-136,F0003,共3页
China Pharmaceuticals
关键词
绝经后妇女
骨质疏松
预防
治疗
进展
postmenopausal women
osteoporosis
prevention
treatment
development
